The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | The potential of CAR-T therapy for the treatment of amyloidosis
In this video, Giampaolo Merlini, MD, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, briefly discusses the promising results observed with the use of CAR-T therapy in multiple myeloma, and the importance of this therapy for the potential treatment of amyloidosis. Prof. Merlini highlights some findings with the use of CAR-T therapy in a patient with myeloma and amyloidosis, and concludes by mentioning the upcoming meeting of the International Society of Amyloidosis (ISA). This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Research support: Amgen, Janssen, BMS, AbbVie, Ionis, Genentech
Honorarium: Amgen, Janssen, Sanofi, Karyopharm, BMS, Astra Zeneca, Adaptive Biotechnologies, Takeda, Pfizer
